Drugs / P30-EPS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05283109 | Aug 2023 → Apr 2025 overdue | malignant glioma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P30-EPS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05283109 ↗ |
| Modality | Vaccine | “Evaluate the safety profile of a cancer vaccine comprised of P30-linked EphA2, CMV pp65, and survivin peptides.” NCT05283109 ↗ |